Can-Fite stock jumps 18% on pancreatic cancer trial data
Investing.com Gold reports: Can-Fite stock jumps 18% on pancreatic cancer trial data. Full body text was unavailable at ingest time, so this brief is based on headline context.
Investing.com Gold reports: Can-Fite stock jumps 18% on pancreatic cancer trial data. Full body text was unavailable at ingest time, so this brief is based on headline context.